TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

E E W Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.